Savolitinib was launched and is marketed under the brand name ORPATHYS ® by our partner, AstraZeneca, for this patient population, representing the first selective MET inhibitor approved in China.

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical Products Administration (“NMPA”) for the ...

A recent population-based study indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying. The findings are published by Wiley ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug ...

New research led by UTHealth Houston scientists uncovered two genes associated with variants linked to epilepsy, which showed specific traits that make them promising diagnostic biomarkers.

When the neurologist showed Amanda her brain scan and confirmed her diagnosis, she broke down emotionally, overwhelmed by the weight of the news. I, on the other hand, was in a state of shock and ...

Kevin Webster’s (Michael Le Vell) worst fears are confirmed in Coronation Street this week as he’s told he has cancer. Earlier this month, the Weatherfield mechanic shocked wife Abi Webster ...

Former talk show host Wendy Williams, whose legal troubles and health battles were documented in a controversial TV documentary and is now confined to an assisted living facility, spoke out ...

Christine Schozer Farr, 34, works as a senior marketing manager at NBC News. Soon after her wedding, she became pregnant but miscarried, which happens in up to 20% of known pregnancies. Then, she ...

AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a treatment of patients with a form of non-small cell lung cancer. The approval by the ...